SEATTLE--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported data from an ongoing phase I weekly-dosing clinical trial of SGN-35, an antibody-drug conjugate (ADC), including multiple complete and partial responses in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL). The data are being presented during a Clinical Science Symposium at the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Orlando, Florida. In addition, data on dacetuzumab (SGN-40) are being presented in a poster session describing a diagnostic gene signature that may identify lymphoma patients who are more likely to respond to dacetuzumab therapy.
